BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Scott Weiner will be moderating a panel, The Partnering Conundrum: To Partner or Not to Partner, That is the Question..., at the Bio 2011 conference in Washington, D.C.
News | 06. 28. 2011
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.